These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32800588)

  • 21. Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data.
    Targher G
    Liver Int; 2020 Nov; 40(11):2879-2880. PubMed ID: 32738082
    [No Abstract]   [Full Text] [Related]  

  • 22. Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
    Méndez-Sánchez N; Maris-Gil S; Alonso-Rivera CG
    J Hepatol; 2022 Jul; 77(1):249. PubMed ID: 34968579
    [No Abstract]   [Full Text] [Related]  

  • 23. Authors' response to 'Concordance of MAFLD and NAFLD diagnostic criteria in "real-world" data'.
    Huang J; Kumar R; Zhu Y; Lin S
    Liver Int; 2020 Nov; 40(11):2880-2881. PubMed ID: 32889767
    [No Abstract]   [Full Text] [Related]  

  • 24. [NASH: new terminology and what else is new in 2020].
    Spahr L; Giostra E; Negro F; Goossens N
    Rev Med Suisse; 2020 Sep; 16(704):1544-1547. PubMed ID: 32880109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Emphasis on clinical study of heterogeneity of non-alcoholic fatty liver disease].
    Huang LJ; Xu YH; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):193-197. PubMed ID: 32306650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From NAFLD to MAFLD: when pathophysiology succeeds.
    Tilg H; Effenberger M
    Nat Rev Gastroenterol Hepatol; 2020 Jul; 17(7):387-388. PubMed ID: 32461575
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical utility of the MAFLD definition.
    Zheng KI; Sun DQ; Jin Y; Zhu PW; Zheng MH
    J Hepatol; 2021 Apr; 74(4):989-991. PubMed ID: 33347953
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation.
    Gill MG; Majumdar A
    World J Hepatol; 2020 Dec; 12(12):1168-1181. PubMed ID: 33442446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MAFLD: A game changer redefining fatty liver disease for adults and children.
    Eslam M; George J
    J Hepatol; 2021 Apr; 74(4):992-994. PubMed ID: 33453327
    [No Abstract]   [Full Text] [Related]  

  • 30. A new definition for non-alcoholic fatty liver disease.
    Poniachik J; Roblero JP; Urzúa A; Cattaneo M
    J Hepatol; 2021 Apr; 74(4):982-983. PubMed ID: 33340572
    [No Abstract]   [Full Text] [Related]  

  • 31. [Non-alcoholic fatty liver disease--What's new].
    Roeb E; Steffen HM; Bojunga J
    Dtsch Med Wochenschr; 2016 Apr; 141(7):494-6. PubMed ID: 27031205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
    Wong VW; Chan WK; Chitturi S; Chawla Y; Dan YY; Duseja A; Fan J; Goh KL; Hamaguchi M; Hashimoto E; Kim SU; Lesmana LA; Lin YC; Liu CJ; Ni YH; Sollano J; Wong SK; Wong GL; Chan HL; Farrell G
    J Gastroenterol Hepatol; 2018 Jan; 33(1):70-85. PubMed ID: 28670712
    [No Abstract]   [Full Text] [Related]  

  • 33. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.
    Aller R; Fernández-Rodríguez C; Lo Iacono O; Bañares R; Abad J; Carrión JA; García-Monzón C; Caballería J; Berenguer M; Rodríguez-Perálvarez M; Miranda JL; Vilar-Gómez E; Crespo J; García-Cortés M; Reig M; Navarro JM; Gallego R; Genescà J; Arias-Loste MT; Pareja MJ; Albillos A; Muntané J; Jorquera F; Solà E; Hernández-Guerra M; Rojo MÁ; Salmerón J; Caballería L; Diago M; Molina E; Bataller R; Romero-Gómez M
    Gastroenterol Hepatol; 2018 May; 41(5):328-349. PubMed ID: 29631866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The epidemiology of non-alcoholic fatty liver disease.
    Bellentani S
    Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China.
    Li H; Guo M; An Z; Meng J; Jiang J; Song J; Wu W
    Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32168920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease.
    Francque S; Lanthier N; Verbeke L; Reynaert H; Van Steenkiste C; Vonghia L; Kwanten WJ; Weyler J; Trépo E; Cassiman D; Smets F; Komuta M; Driessen A; Dirinck E; Danse E; Op de Beeck B; van Craenenbroeck E; Van Nieuwenhove Y; Hubens G; Geerts A; Moreno C
    Acta Gastroenterol Belg; 2018; 81(1):55-81. PubMed ID: 29562379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnosis and therapeutic strategies for non-obese type of non-alcoholic fatty liver diseases].
    Chen HT; Zhou YJ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):203-207. PubMed ID: 32306652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the Proposed Definition of Metabolic-Associated Fatty Liver Disease.
    Wai-Sun Wong V; Kanwal F
    Clin Gastroenterol Hepatol; 2021 May; 19(5):865-870. PubMed ID: 33453398
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
    Riou J; Canivet CM; Boursier J
    J Hepatol; 2020 Aug; 73(2):466-467. PubMed ID: 32423633
    [No Abstract]   [Full Text] [Related]  

  • 40. [Expert recommendations on standardized diagnosis and treatment for fatty liver disease in China (2019 revised edition)].
    ; ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2019 Oct; 27(10):748-753. PubMed ID: 31734987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.